2 Amendments of Catherine BEARDER related to 2017/0328(COD)
Amendment 12 #
Draft legislative resolution
Paragraph 2 a (new)
Paragraph 2 a (new)
2 a. Notes that while expertise will be developed over time, the loss of the UK’s national competent authority, the Medicines and Healthcare products Regulatory Agency (MHRA), to the joint pool of expertise available under the EMA could be detrimental to the scientific approval of medicines for the EU market in the interim. In 2016, the MHRA led 20 per cent of scientific evaluations of new medicines for the EMA.1b _________________ 1bhttp://www.nhsconfed.org/regions-and- eu/nhs-european-office/brexit/brexit- health-alliance/access-to-medicines-and- medical-technologies
Amendment 17 #
Draft legislative resolution
Paragraph 2 b (new)
Paragraph 2 b (new)
2 b. Regrets that the relocation of the EMA to Amsterdam has meant that the agency has had to temporarily de- prioritise certain activities, such as its work on paediatric medicines and public health issues. This includes its work on anti-microbial resistance and flu pandemics.1a _________________ 1a http://www.ema.europa.eu/docs/en_GB/do cument_library/Other/2017/10/WC500236 755.pdf